SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who had disease progression during or following platinum-based chemotherapy in the metastatic set
Recent tooth loss and periodontal disease appears to be associated with the risk for primary open-angle glaucoma, especially cases with early paracentral visual field loss, new research shows. Medscape Medical News
PHILADELPHIA – Jetrea injection resulted in vitreomacular traction release in more than half of cases, a speaker here said, relating the Wills Eye experience with the treatment.The presentation won the James S. Shipman Award for best paper during the Wills Eye Alumni Conference paper session.
FORT LAUDERDALE, Fla. — At all dose strengths, a bimatoprost sustained-release implant was well tolerated and comparable to topical bimatoprost in overall IOP reduction, according to 6-month interim results of a phase 1/2 study.“We need something better than eye drops, so we’re all looking for that right way to lower pressure with a sustained delivery device,” E. Randy Craven, MD, said at the American Glaucoma Society meeting.
Macular epiretinal brachytherapy combined with ranibizumab did not reduce the number of ranibizumab injections that patients required for the treatment of neovascular age-related macular degeneration, according to a study.Principal investigator Tim Jac…
Thomas Bayes died in 1761, but his theorem lives on and is inspiring a new generation of statistical thinking. Whether you are frequentist or Bayesian, Jack S. Parker, MD, shares a compelling argument for us to ditch the P